Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Łukasz Działach"'
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
Ectopic ACTH syndrome (EAS) remains one of the most demanding diagnostic and therapeutic challenges for endocrinologists. Thymic neuroendocrine tumors account for 5%–10% of all EAS cases. We report a unique case of a 31-year-old woman with severe E
Externí odkaz:
https://doaj.org/article/462853d19421417e823a8c3ef0f6897e
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
Prolactinomas (PRLomas) constitute approximately half of all pituitary adenomas and approximately one-fifth of them are diagnosed in males. The clinical presentation of PRLomas results from direct prolactin (PRL) action, duration and severity of hype
Externí odkaz:
https://doaj.org/article/881123ca516c4d9f9b50c6bb29e083c9
Autor:
Lukasz Dzialach, Joanna Sobolewska, Wioleta Respondek, Katarzyna Szamotulska, Przemysław Witek
Publikováno v:
Biomedicines, Vol 11, Iss 12, p 3227 (2023)
Osilodrostat is a potent oral steroidogenesis inhibitor that has emerged as the new medical agent for patients with Cushing’s disease (CD) requiring long-term medical therapy for hypercortisolemia control. Its efficacy and safety have been assessed
Externí odkaz:
https://doaj.org/article/98315790c2ca4296a4be1c4babe28a53
Autor:
Paulina Kober, Natalia Rusetska, Beata J. Mossakowska, Maria Maksymowicz, Monika Pękul, Grzegorz Zieliński, Andrzej Styk, Jacek Kunicki, Łukasz Działach, Przemysław Witek, Mateusz Bujko
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
ObjectivePituitary neuroendocrine corticotroph tumors commonly cause Cushing’s disease (CD) that results from increased adrenocorticotropic hormone (ACTH) secretion by the pituitary tumor and consequent increase of cortisol levels in blood. However
Externí odkaz:
https://doaj.org/article/1a1d87f12f4d44ccbbb3de019e753037
Autor:
Monika Obara-Moszynska, Lukasz Dzialach, Barbara Rabska-Pietrzak, Marek Niedziela, Karina Kapczuk
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
ObjectiveMost girls and women with Turner syndrome (TS) require estrogen replacement therapy (ERT) to initiate or maintain pubertal development. Most likely, the most fundamental effect of ERT in hypogonadism is the promotion of uterine growth. The o
Externí odkaz:
https://doaj.org/article/e7403c0b4f6e4cc1830ae53c2c1eebc5